Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities

Meghan J Chenoweth^{1

2}, Kathleen M Giacomini³, Munir Pirmohamed⁴, Susan L Hill⁵, Ron H N van Schaik⁶, Matthias Schwab^{7

8

9}, Alan R Shuldiner^{10

11}, Mary V Relling¹², Rachel F Tyndale^{1

2

13}

Affiliations

¹ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
² Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
³ Department of Bioengineering and Therapeutic Sciences, University of California - San Francisco, San Francisco, California, USA.
⁴ Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
⁵ National Health Service (NHS), London, UK.
⁶ Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
⁷ Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
⁸ Department of Clinical Pharmacology and of Biochemistry and Pharmacy, University of Tübingen, Tübingen, Germany.
⁹ iFIT Cluster of Excellence, University of Tübingen, Tübingen, Germany.
¹⁰ Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
¹¹ Program in Personalized and Genomic Medicine and Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
¹² Pharmaceutical Sciences Department, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
¹³ Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.

Meghan J Chenoweth et al. Clin Pharmacol Ther. 2020 Jan.

. 2020 Jan;107(1):57-61.

doi: 10.1002/cpt.1664. Epub 2019 Nov 6.

¹ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
² Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
³ Department of Bioengineering and Therapeutic Sciences, University of California - San Francisco, San Francisco, California, USA.
⁴ Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
⁵ National Health Service (NHS), London, UK.
⁶ Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
⁷ Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
⁸ Department of Clinical Pharmacology and of Biochemistry and Pharmacy, University of Tübingen, Tübingen, Germany.
⁹ iFIT Cluster of Excellence, University of Tübingen, Tübingen, Germany.
¹⁰ Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
¹¹ Program in Personalized and Genomic Medicine and Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
¹² Pharmaceutical Sciences Department, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
¹³ Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.

No abstract available

References

1. Volpi S et al. Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. Clin Pharmacol Ther 103, 778–86 (2018). - PMC - PubMed
1. Bergmeijer TO et al. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). Am Heart J 198, 152–9 (2018). - PMC - PubMed
1. Backman JD et al. Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response. Pharmacogenet Genom 27, 159–63 (2017). - PMC - PubMed
1. Chu XY et al. Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. Clinical Pharmacology & Therapeutics 104, 836–64 (2018). - PubMed
1. Jorgensen AL et al. Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. BMC Med 17:76, 1–11 (2019). - PMC - PubMed